Sourasky Medical Center (Ichilov)
Sourasky Medical Center (Ichilov)
Israel, Telavive
Ofer Merimsky
41 anos de experiência
acreditações :
Clínica certificada :
| Israel | Turquia | Áustria | |
| Terapia de protão | de $48,000 | de $70,000 | de $80,000 |
| Quimioterapia para cancro da mama | de $22,500 | de $1,200 | de $15,000 |
| Quimioterapia Intraperitoneal Hipertérmica (HIPEC) | de $61,200 | de $22,500 | de $40,000 |
| Prostatectomia robótica da Vinci | de $24,570 | de $17,000 | de $20,000 |
| CyberKnife | de $17,500 | de $4,750 | de $50,000 |
A Clínica Assuta é o maior centro médico privado de Israel. O hospital especializa-se em oncologia, ortopedia, neurocirurgia, cirurgia cardíaca e tratamento de infertilidade. 13% de todas as operações no país são realizadas na Assuta, o que a torna um centro cirúrgico líder.
Pela qualidade e segurança no tratamento, o hospital recebeu a acreditação americana da Joint Commission International.
Anualmente, os médicos da rede Assuta realizam mais de 92.000 operações, 685.000 procedimentos diagnósticos e 16.000 ciclos de FIV.
Chefe da Unidade de Oncologia de Tecidos Moles e Ósseos do Sourasky Medical Center – O Dr. Merimsky é especialista em casos complexos de sarcoma.
A Dra. Pelles Sharon é especialista em tratamentos avançados de adenocarcinoma no Sourasky Medical Center, incluindo HIPEC e imunoterapia.
O Dr. Sarid é especialista em quimioterapia e radioterapia, com mais de 25 anos de experiência em oncologia no Sourasky (Ichilov) Medical Center, líder em Israel.
Dr. Arnon Nagler is an internationally recognized hematologist and bone marrow transplant expert. He is a Professor of Medicine at Tel Aviv University. He is Director Emeritus of Hematology & Bone Marrow Transplantation and the Cord Blood Bank at Sheba Medical Center. He earned his M.D. from the Hebrew University–Hadassah and an M.Sc. in hematopoiesis from Tel Aviv University. He completed postdoctoral training at Stanford. He is board certified in internal medicine and hematology.
He has more than 35 years of experience. He pioneered reduced‑intensity allogeneic transplant protocols for malignant and non‑malignant diseases. He founded Israel’s first public cord blood bank. He performed the country’s first cord blood transplants.
He has held international leadership roles. He served as Chair and Co‑Chair of the ALWP of the EBMT. He was a vice‑chair and long‑term member of EBMT committees. He served on the board of NetCord/EuroCord and as treasurer. He is a frequent invited speaker. He has published widely in journals such as Blood and Leukemia. He has led major clinical trials as a principal investigator and held editorial roles. He has received multiple awards for innovation and clinical excellence.